Bicalutamide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Bicalutamide
Bicalutamide.svg
Bicalutamide ball-and-stick.png
Systematic (IUPAC) name
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
Clinical data
Trade names Casodex
AHFS/Drugs.com monograph
MedlinePlus a697047
Pregnancy
category
  • US: X (Contraindicated)
Legal status
  • (Prescription only)
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability Well-absorbed
Protein binding 96%
Metabolism Hepatic (CYP3A4)
Biological half-life 6 days
Identifiers
CAS Registry Number 90357-06-5 YesY
ATC code L02BB03
PubChem CID: 2375
IUPHAR/BPS 2863
DrugBank DB01128 YesY
ChemSpider 2284 YesY
UNII A0Z3NAU9DP YesY
KEGG D00961 N
ChEMBL CHEMBL63560 N
Synonyms ICI-176334[1]
PDB ligand ID 198 (PDBe, RCSB PDB)
Chemical data
Formula C18H14F4N2O4S
Molecular mass 430.373 g/mol
 N (what is this?)  (verify)

Bicalutamide (INN, USAN, BAN) (brand names Casodex, Cosudex, Calutide, Kalumid) is a synthetic, non-steroidal, peripherally-selective, pure antiandrogen used in the treatment of prostate cancer,[2][3][4] hirsutism,[5][6] and other androgen-dependent conditions.[1][7][8] Developed and marketed by AstraZeneca,[9] bicalutamide was approved in 1995 as a combination treatment (with a gonadotropin-releasing hormone (GnRH) analogue (e.g., leuprorelin) or surgical castration)[10][11] for advanced prostate cancer and has since also been used as a monotherapy for the treatment of earlier stages of the disease.[12] Prior to the approval of enzalutamide, a recently introduced, newer non-steroidal antiandrogen with theoretically improved effectiveness, bicalutamide was regarded as the standard-of-care antiandrogen for the treatment of prostate cancer.[13]

Indications[edit]

Bicalutamide is indicated for the treatment of stage D2 metastatic prostate cancer in combination with castration (pharmacological with a GnRH analogue or surgical with an orchiectomy)[14] or as a monotherapy.[15] However, while effective, most advanced prostate cancer patients eventually become resistant to antiandrogen including bicalutamide therapy.[16]

Relative to the other non-steroidal antiandrogens flutamide and nilutamide, bicalutamide has the highest affinity for the androgen receptor (AR) (e.g., 4-fold greater than flutamide),[17] as well as the longest half-life (~6 days for bicalutamide versus 5–6 hours for flutamide and ~2 days for nilutamide).[18] Bicalutamide is described as the most potent of the non-steroidal antiandrogens as well as the most well-tolerated (not including/considering enzalutamide).[19] It is for these reasons, as well as a better safety profile, that bicalutamide has largely replaced flutamide and nilutamide in the treatment of prostate cancer.[20]

Low-dose bicalutamide has been found to be effective in the treatment of hirsutism in women.[5][6][21]

Bicalutamide, along with other non-steroidal antiandrogens including flutamide and nilutamide, is used as a component of hormone replacement therapy for trans women.[22][23] However, relative to flutamide and nilutamide, bicalutamide is, in general, clinically preferred due to its superior safety, tolerability, and pharmacokinetic profiles.[18][24]

In clinical studies, flutamide has been found to be more effective than both spironolactone and cyproterone acetate in the treatment of androgen-dependent conditions such as acne and hirsutism in women.[25][26][27] Bicalutamide has similarly been tried and found to be effective in the treatment of hirsutism in women.[5][6][21] However, although it has not been compared head-to-head with other antiandrogens in any trials, relative to flutamide, as mentioned above, bicalutamide is several times more potent and has a much longer half-life, and hence would be expected to be at least equivalent or perhaps even more effective in comparison.[17][18]

It is noteworthy that monotherapy with non-steroidal, pure antiandrogens including flutamide and bicalutamide increases androgen and estrogen levels in men, but that this does not occur in women.[28][29][30] As such, bicalutamide on its own may be relatively more effective as an antiandrogen in women. However, monotherapy with higher dosages of bicalutamide (150 mg/day) has still been found to be highly effective in the treatment of prostate cancer in men, and thus as an antiandrogen.[12]

Bicalutamide has been tested with good results for the treatment of AR-positive ER/PR-negative locally advanced and metastatic breast cancer in a phase II study and has been used off-label for this indication.[31][32][33] The newer non-steroidal antiandrogen enzalutamide may also hold some promise for this type of cancer but has been so far tested only in vitro.[citation needed] Bicalutamide has also been researched in clinical trials for ovarian cancer, with effectiveness seen.[34]

Dosage[edit]

Bicalutamide is used in dosages of 50 mg/day in combination with a GnRH analogue in the treatment of prostate cancer and at a dosage of 150 mg/day as a monotherapy for prostate cancer.[19]

Bicalutamide has been used at a dosage of 25 mg/day in the treatment of hirsutism in women.[5][6][21]

Contraindications[edit]

Due to its actions as an antiandrogen, bicalutamide is a teratogen and should not be handled by women who are or who may become pregnant.[35][36] It is known to have the potential to cause fetal defects, such as ambiguous genitalia.[35][36]

In individuals with moderate-to-severe hepatic impairment, bicalutamide should be used with caution.[37]

Adverse effects[edit]

Known potential side effects of bicalutamide, some of which may include breast pain/tenderness, gynecomastia, hot flashes, depression, fatigue, sexual dysfunction (including loss of libido and erectile dysfunction),[17] diarrhea, nausea, pruritus (itching), and, rarely, hepatic changes (e.g., transiently elevated levels of transaminases, jaundice[38]).[39][40][41][42]

Some of the above-listed side effects, including breast pain/tenderness and gynecomastia, are far less likely to occur when bicalutamide is combined with a GnRH analogue (due to suppression of estrogen levels),[43] and others, including hot flashes, depression, fatigue, and loss of libido,[44] may occur only or may occur much more often when bicalutamide is combined with a GnRH analogue.[45][46] In regards to the latter side effects, this is because bicalutamide is peripherally-selective and does not antagonize androgen action in the brain,[44][47] and by itself, does not lower androgen levels.[48] As such, brain androgen action remains normal or even increased with bicalutamide monotherapy (as bicalutamide by itself increases serum androgen levels[48]).[44][47]

From a theoretical standpoint, flutamide, nilutamide, and bicalutamide are all thought to be capable of causing hepatotoxicity,[20][49] However, relative to flutamide (which has an estimated incidence rate of 3 in every 10,000, or 0.0003%), hepatotoxicity is much rarer in nilutamide and bicalutamide, and the risk is thought to be significantly less with nilutamide and even further less with bicalutamide.[49][50][51] A total of four cases of bicalutamide-associated hepatotoxicity have been reported in the medical literature.[38]

A few cases of interstitial pneumonitis in association with bicalutamide treatment have been reported in the medical literature.[41][52][53] Incidence is very rare, and the risk of interstitial pneumonitis is far less relative to that seen with nilutamide.[52]

Pharmacology[edit]

Bicalutamide acts as a potent and highly selective competitive silent antagonist of the androgen receptor (AR). This prevents the activation of the AR and subsequent upregulation of androgen-responsive genes by androgens such as testosterone and dihydrotestosterone (DHT).[47][54] Bicalutamide has also notably been found to accelerate the degradation of the AR.[55] Owing to its selectivity, unlike steroidal antiandrogens such as cyproterone acetate and megestrol acetate,[56] bicalutamide does not additionally inhibit or suppress androgen production in the body – instead, it exclusively blocks androgen binding and subsequent receptor activation at the level of the AR.[57]

Bicalutamide, unlike flutamide,[58] nilutamide,[59] and enzalutamide,[60] poorly crosses the blood-brain-barrier, and so is limited in its ability to block the actions of androgens in the central nervous system.[47] However, there is possible evidence that the peripheral selectivity of bicalutamide may only be the case in animals (including in rats and dogs)[61][62][63] and not in humans,[64][65][66] due to species-related differences in drug tissue distribution.[65][66] In any case, although bicalutamide may cause some sexual difficulties (e.g., erectile dysfunction) and reduced ejaculate volume and sperm count, monotherapy with the drug appears to have minimal effect on sexual desire as well as on sexual activity.[44] These findings support the idea that bicalutamide indeed only minimally crosses the blood-brain-barrier in humans.[44]

Blockade of the AR by bicalutamide in the pituitary gland (which lies outside of the blood-brain-barrier) suppresses the negative feedback of androgens on the release of luteinizing hormone (LH). This, in turn, leads to a significant increase in androgen and estrogen levels.[48] Bicalutamide will more than block the effects of the increased androgen levels in the periphery (monotherapy is still highly effective in the treatment of prostate cancer, to demonstrate),[12] but the effect of the elevated estrogen levels will remain unopposed and lead to feminizing effects, most notably gynecomastia,[67] and the increased levels of androgens will not be blocked in the brain (since bicalutamide only poorly crosses the blood-brain-barrier),[47] which may be considered a benefit or a detriment based on the particular situation (for instance, increased androgen action in the brain might not be desirable to or for some women, while in other individuals, both male and female, effects such as potentially heightened libido may be welcomed).

If bicalutamide is combined with a GnRH analogue or surgical castration, the elevation of androgen and estrogen levels will be prevented and the risks of excessive estrogens, such as gynecomastia, will be reduced.[43] However, since both androgens and estrogens are essential for normal bone metabolism, reducing the anabolic bone effects of both androgens (which increase bone formation by stimulating osteoblasts)[68] and estrogens (which reduce bone resorption by inhibiting osteoclasts)[69] will increase bone loss and promote osteoporosis.[70] In addition, hot flashes, depression, fatigue, and loss of libido are much more likely to occur when bicalutamide is combined with a GnRH analogue.[45][46]

The activity of bicalutamide lies in the R-isomer, which binds to the AR with an affinity that is about 30-fold higher than that of the S-isomer.[57] The active R-isomer also has a much longer half-life than the S-isomer.[57] At steady-state, serum levels of (R)-bicalutamide are about 100-fold greater than those of (S)-bicalutamide.[71]

Pharmacokinetics[edit]

Bicalutamide has a very long serum half-life of about 6 days with a single dose,[19] and a half-life of 7–10 days with repeated administration, allowing for once-daily dosing.[51]

Bicalutamide is almost exclusively metabolized by the enzyme CYP3A4.[71][72]

It has been reported that bicalutamide may have the potential to inhibit the enzymes CYP3A4 and, to a lesser extent, CYP2C9, CYP2C19, and CYP2D6, based on in vitro research.[72] However, no relevant inhibition of CYP3A4 has been observed in vivo with bicalutamide at a dose of 150 mg (using midazolam as a specific marker of CYP3A4).[72] In animals, bicalutamide has been found to be an inducer of certain cytochrome P450 enzymes.[72] However, dosages of 150 mg/day or less have shown no evidence of this in humans.[72]

See also[edit]

References[edit]

  1. ^ a b I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 51–. ISBN 978-94-011-4439-1. 
  2. ^ Schellhammer PF (Sep 2002). "An evaluation of bicalutamide in the treatment of prostate cancer". Expert Opinion on Pharmacotherapy 3 (9): 1313–28. doi:10.1517/14656566.3.9.1313. PMID 12186624. 
  3. ^ Kunkler I, James N, Maher J (Feb 2004). "Bicalutamide (Casodex) in the treatment of prostate cancer". Expert Review of Anticancer Therapy 4 (1): 37–48. doi:10.1586/14737140.4.5.S37. PMID 14748655. 
  4. ^ See WA, Tyrrell CJ (Aug 2006). "The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer". Journal of Cancer Research and Clinical Oncology. 132 Suppl 1: S7–16. doi:10.1007/s00432-006-0132-6. PMID 16896884. 
  5. ^ a b c d Erem C (2013). "Update on idiopathic hirsutism: diagnosis and treatment". Acta Clin Belg 68 (4): 268–74. doi:10.2143/ACB.3267. PMID 24455796. 
  6. ^ a b c d Müderris II, Bayram F, Ozçelik B, Güven M (Feb 2002). "New alternative treatment in hirsutism: bicalutamide 25 mg/day". Gynecological Endocrinology 16 (1): 63–6. doi:10.1080/713602986. PMID 11915584. 
  7. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 123–. ISBN 978-3-88763-075-1. 
  8. ^ C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 570–. ISBN 978-0-412-46630-4. 
  9. ^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 627–. ISBN 978-0-8155-1856-3. 
  10. ^ Klotz L (May 2006). "Combined androgen blockade: an update". The Urologic Clinics of North America 33 (2): 161–6, v–vi. doi:10.1016/j.ucl.2005.12.001. PMID 16631454. 
  11. ^ Wellington K, Keam SJ (2006). "Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer". Drugs 66 (6): 837–50. doi:10.2165/00003495-200666060-00007. PMID 16706554. 
  12. ^ a b c John A.H. Wass; Paul M. Stewart (28 July 2011). Oxford Textbook of Endocrinology and Diabetes. OUP Oxford. pp. 1625–. ISBN 978-0-19-923529-2. 
  13. ^ Vera Regitz-Zagrosek (2 October 2012). Sex and Gender Differences in Pharmacology. Springer Science & Business Media. pp. 575–. ISBN 978-3-642-30725-6. 
  14. ^ Klotz L, Schellhammer P (Mar 2005). "Combined androgen blockade: the case for bicalutamide". Clinical Prostate Cancer 3 (4): 215–9. doi:10.3816/cgc.2005.n.002. PMID 15882477. 
  15. ^ Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ (Sep 1997). "Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group". Urology 50 (3): 330–6. doi:10.1016/S0090-4295(97)00279-3. PMID 9301693. 
  16. ^ Balk SP (Sep 2002). "Androgen receptor as a target in androgen-independent prostate cancer". Urology 60 (3 Suppl 1): 132–8; discussion 138–9. doi:10.1016/S0090-4295(02)01593-5. PMID 12231070. 
  17. ^ a b c Martin I. Resnick; Ian Murchie Thompson (2000). Advanced Therapy of Prostate Disease. PMPH-USA. pp. 379–. ISBN 978-1-55009-102-1. 
  18. ^ a b c James Leonard Gulley (2011). Prostate Cancer. Demos Medical Publishing. pp. 81–. ISBN 978-1-935281-91-7. 
  19. ^ a b c Alan J. Wein; Louis R. Kavoussi; Andrew C. Novick; Alan W. Partin, Craig A. Peters (25 August 2011). Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set. Elsevier Health Sciences. pp. 2939–. ISBN 978-1-4160-6911-9. 
  20. ^ a b Chris M. Bunce; Moray J. Campbell (11 March 2010). Nuclear Receptors: Current Concepts and Future Challenges. Springer Science & Business Media. pp. 160–. ISBN 978-90-481-3303-1. 
  21. ^ a b c Hywel Williams; Michael Bigby; Thomas Diepgen; Andrew Herxheimer; Luigi Naldi; Berthold Rzany (22 January 2009). Evidence-Based Dermatology. John Wiley & Sons. pp. 529–. ISBN 978-1-4443-0017-8. 
  22. ^ Gooren, Louis J. (2011). "Care of Transsexual Persons". New England Journal of Medicine 364 (13): 1251–1257. doi:10.1056/NEJMcp1008161. ISSN 0028-4793. 
  23. ^ Ho CK (2011). "Testosterone testing in adult males". Malays J Pathol 33 (2): 71–81. PMID 22299206. 
  24. ^ Lutz Moser (1 January 2008). Controversies in the Treatment of Prostate Cancer. Karger Medical and Scientific Publishers. pp. 41–42. ISBN 978-3-8055-8524-8. 
  25. ^ Robert S. Haber; Dowling Bluford Stough (2006). Hair Transplantation. Elsevier Health Sciences. p. 6. ISBN 978-1-4160-3104-8. Retrieved 28 May 2012. 
  26. ^ Allan H. Goroll; Albert G. Mulley (27 January 2009). Primary Care Medicine: Office Evaluation and Management of the Adult Patient. Lippincott Williams & Wilkins. p. 1264. ISBN 978-0-7817-7513-7. Retrieved 28 May 2012. 
  27. ^ Grigoriou O, Papadias C, Konidaris S, Antoniou G, Karakitsos P, Giannikos L (April 1996). "Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial". Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology 10 (2): 119–23. doi:10.3109/09513599609097901. PMID 8701785. 
  28. ^ Evanthia Diamanti-Kandarakis; John E. Nestler; Dimitrios Panidis; Renato Pasquali (21 December 2009). Insulin Resistance and Polycystic Ovarian Syndrome: Pathogenesis, Evaluation, and Treatment. Springer Science & Business Media. pp. 75–. ISBN 978-1-59745-310-3. 
  29. ^ Douglas T. Carrell; C. Matthew Peterson (23 March 2010). Reproductive Endocrinology and Infertility: Integrating Modern Clinical and Laboratory Practice. Springer Science & Business Media. pp. 163–. ISBN 978-1-4419-1436-1. 
  30. ^ Journal of Reproductive Medicine. Journal of Reproductive Medicine, Incorporated. July 1994. 
  31. ^ http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94715
  32. ^ http://clinicaltrials.gov/ct2/show/NCT00468715
  33. ^ Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA (Oct 2013). "Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer". Clinical Cancer Research 19 (19): 5505–12. doi:10.1158/1078-0432.CCR-12-3327. PMC 4086643. PMID 23965901. 
  34. ^ Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Iasonos A, Sabbatini P (Dec 2007). "A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission". Cancer 110 (11): 2448–56. doi:10.1002/cncr.23072. PMID 17918264. 
  35. ^ a b Iswaran, T.J.; Imai, M.; Betton, G.R.; Siddall, R.A. (1997). "An overview of animal toxicology studies with bicalutamide (ICI 176, 334).". The Journal of Toxicological Sciences 22 (2): 75–88. doi:10.2131/jts.22.2_75. ISSN 0388-1350. 
  36. ^ a b Robert E. Smith (4 April 2013). Medicinal Chemistry - Fusion of Traditional and Western Medicine. Bentham Science Publishers. pp. 306–. ISBN 978-1-60805-149-6. 
  37. ^ Roland T. Skeel; Samir N. Khleif (2011). Handbook of Cancer Chemotherapy. Lippincott Williams & Wilkins. pp. 724–. ISBN 978-1-60831-782-0. 
  38. ^ a b Jafri, Syed-Mohammed R. (2014). "Bicalutamide-induced hepatotoxicity: A rare adverse effect". American Journal of Case Reports 15: 266–270. doi:10.12659/AJCR.890679. ISSN 1941-5923. 
  39. ^ Lunglmayr G (Aug 1995). "Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group". Anti-Cancer Drugs 6 (4): 508–13. doi:10.1097/00001813-199508000-00003. PMID 7579554. 
  40. ^ McLeod DG (1997). "Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer". The Oncologist 2 (1): 18–27. PMID 10388026. 
  41. ^ a b Richard C. Dart (2004). Medical Toxicology. Lippincott Williams & Wilkins. pp. 521–. ISBN 978-0-7817-2845-4. 
  42. ^ Lisa M DeAngelis MD; Jerome B Posner MD (12 September 2008). Neurologic Complications of Cancer. Oxford University Press, USA. pp. 479–. ISBN 978-0-19-971055-3. 
  43. ^ a b Jean-Pierre Droz; Riccardo A. Audisio (2 October 2012). Management of Urological Cancers in Older People. Springer Science & Business Media. pp. 84–. ISBN 978-0-85729-986-4. 
  44. ^ a b c d e Mason M (Aug 2006). "What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?". Journal of Cancer Research and Clinical Oncology. 132 Suppl 1: S27–35. doi:10.1007/s00432-006-0134-4. PMID 16896883. 
  45. ^ a b Michael L. Cher; Kenneth V. Honn; Avraham Raz (11 April 2006). Prostate Cancer: New Horizons in Research and Treatment. Springer Science & Business Media. pp. 382–. ISBN 978-0-306-48143-7. 
  46. ^ a b David Feldman; Robert Marcus; Dorothy Nelson; Clifford J. Rosen (8 November 2007). Osteoporosis. Academic Press. pp. 1354–. ISBN 978-0-08-055347-4. 
  47. ^ a b c d e Furr BJ, Tucker H (Jan 1996). "The preclinical development of bicalutamide: pharmacodynamics and mechanism of action". Urology 47 (1A Suppl): 13–25; discussion 29–32. doi:10.1016/S0090-4295(96)80003-3. PMID 8560673. 
  48. ^ a b c Eri LM, Haug E, Tveter KJ (Mar 1995). "Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia". British Journal of Urology 75 (3): 335–40. doi:10.1111/j.1464-410X.1995.tb07345.x. PMID 7537602. 
  49. ^ a b Patrick Dansette; Robert R. Snyder; Terrence J. Monks; David J. Jollow, I. Glenn Sipes, Helmut Greim, G. Gordon Gibson, Marcel Delaforge (6 December 2012). Biological Reactive Intermediates Vi: Chemical and Biological Mechanisms in Susceptibility to and Prevention of Environmental Diseases. Springer Science & Business Media. pp. 37–. ISBN 978-1-4615-0667-6. 
  50. ^ J. Ramon; L.J. Denis (5 June 2007). Prostate Cancer. Springer Science & Business Media. pp. 256–. ISBN 978-3-540-40901-4. 
  51. ^ a b Virgil Craig Jordan; B. J. A. Furr (5 February 2010). Hormone Therapy in Breast and Prostate Cancer. Springer Science & Business Media. pp. 356–. ISBN 978-1-59259-152-7. 
  52. ^ a b Masago, Toshihiko; Watanabe, Takeshi; Nemoto, Ryosuke; Motoda, Kinya (2011). "Interstitial pneumonitis induced by bicalutamide given for prostate cancer". International Journal of Clinical Oncology 16 (6): 763–765. doi:10.1007/s10147-011-0239-x. ISSN 1341-9625. 
  53. ^ Jeffrey K Aronson (4 March 2014). Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions. Newnes. pp. 740–. ISBN 978-0-444-62636-3. 
  54. ^ Furr BJ (1996). "The development of Casodex (bicalutamide): preclinical studies". European Urology. 29 Suppl 2: 83–95. PMID 8717469. 
  55. ^ Waller AS, Sharrard RM, Berthon P, Maitland NJ (Jun 2000). "Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex". Journal of Molecular Endocrinology 24 (3): 339–51. doi:10.1677/jme.0.0240339. PMID 10828827. 
  56. ^ Chawnshang Chang (1 January 2005). Prostate Cancer: Basic Mechanisms and Therapeutic Approaches. World Scientific. pp. 11–. ISBN 978-981-256-920-2. 
  57. ^ a b c Jan H. M. Schellens; Howard L. McLeod; David R. Newell (5 May 2005). Cancer Clinical Pharmacology. OUP Oxford. pp. 229–. ISBN 978-0-19-262966-1. 
  58. ^ Hormones - Antineoplastics: Advances in Research and Application: 2011 Edition: ScholarlyPaper. ScholarlyEditions. 9 January 2012. pp. 9–. ISBN 978-1-4649-4785-8. 
  59. ^ Raynaud, Jean-Pierre; Bonne, Claude; Bouton, Marie-Madeleine; Lagace, Lisette; Labrie, Fernand (1979). "Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues". Journal of Steroid Biochemistry 11 (1): 93–99. doi:10.1016/0022-4731(79)90281-4. ISSN 0022-4731. 
  60. ^ Wm Kevin Kelly; Edouard J. Trabulsi, MD; Nicholas G. Zaorsky, MD (17 December 2014). Prostate Cancer: A Multidisciplinary Approach to Diagnosis and Management. Demos Medical Publishing. pp. 342–. ISBN 978-1-936287-59-8. 
  61. ^ Furr, B.J.A. (1989). "“Casodex”(ICI 176,334) – A New, Pure, Peripherally-Selective Anti-Androgen: Preclinical Studies". Hormone Research 32 (1): 69–76. doi:10.1159/000181315. ISSN 1423-0046. 
  62. ^ Furr, B.J.A.; Tucker, H. (1996). "The preclinical development of bicalutamide: pharmacodynamics and mechanism of action". Urology 47 (1): 13–25. doi:10.1016/S0090-4295(96)80003-3. ISSN 0090-4295. PMID 8560673. 
  63. ^ Furr, B.J.A.; Valcaccia, B.; Curry, B.; Woodburn, J.R.; Chesterson, G.; Tucker, H. (1987). "ICI 176,334: A NOVEL NON-STEROIDAL, PERIPHERALLY SELECTIVE ANTIANDROGEN". Journal of Endocrinology 113 (3): R7–R9. doi:10.1677/joe.0.113R007. ISSN 0022-0795. 
  64. ^ Soloway, Mark S.; Schellhammer, Paul F.; Smith, Joseph A. Jr.; Chodak, Gerald W.; Vogelzang, Nicholas J.; Kennealey, Gerard T. (1995). "Bicalutamide in the Treatment of Advanced Prostatic Carcinoma: A Phase II Noncomparative Multicenter Trial Evaluating Safety, Efficacy and Long-Term Endocrine Effects of Monotherapy". The Journal of Urology 154 (6): 2110–2114. doi:10.1016/S0022-5347(01)66709-0. ISSN 0022-5347. 
  65. ^ a b Cockshott ID (2004). "Bicalutamide: clinical pharmacokinetics and metabolism". Clin Pharmacokinet 43 (13): 855–78. doi:10.2165/00003088-200443130-00003. PMID 15509184. 
  66. ^ a b Gao, Wenqing; Dalton, James T. (2007). "Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)". Drug Discovery Today 12 (5-6): 241–248. doi:10.1016/j.drudis.2007.01.003. ISSN 1359-6446. 
  67. ^ Sieber PR (Dec 2007). "Treatment of bicalutamide-induced breast events". Expert Review of Anticancer Therapy 7 (12): 1773–9. doi:10.1586/14737140.7.12.1773. PMID 18062751. 
  68. ^ Kasperk CH, Wergedal JE, Farley JR, Linkhart TA, Turner RT, Baylink DJ (Mar 1989). "Androgens directly stimulate proliferation of bone cells in vitro". Endocrinology 124 (3): 1576–8. doi:10.1210/endo-124-3-1576. PMID 2521824. 
  69. ^ Manolagas SC, Jilka RL, Girasole G, Passeri G, Bellido T (1993). "Estrogen, cytokines, and the control of osteoclast formation and bone resorption in vitro and in vivo". Osteoporosis International. 3 Suppl 1: 114–6. doi:10.1007/BF01621882. PMID 8461536. 
  70. ^ Vanderschueren D, Gaytant J, Boonen S, Venken K (Jun 2008). "Androgens and bone". Current Opinion in Endocrinology, Diabetes, and Obesity 15 (3): 250–4. doi:10.1097/MED.0b013e3282fe6ca9. PMID 18438173. 
  71. ^ a b Thomas L. Lemke; David A. Williams (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1372–1373. ISBN 978-1-60913-345-0. 
  72. ^ a b c d e Cockshott, Ian D (2004). "Bicalutamide". Clinical Pharmacokinetics 43 (13): 855–878. doi:10.2165/00003088-200443130-00003. ISSN 0312-5963. PMID 15509184. 

External links[edit]